Large B-Cell Lymphomas in the 5th Edition of the WHO-Classification of Haematolymphoid Neoplasms—Updated Classification and New Concepts
Cancers · 13.04.2023 · 15 (8) · 2285
DOI: 10.3390/cancers15082285 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 13.04.2023. Verfasst von Katrin S Kurz und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pathology, Robert-Bosch-Krankenhaus, 70376 Stuttgart, Germany. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 236 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Robert-Bosch-Stiftung (project O3), Stuttgart, Germany. Project 3.2.4., Forschungsstipendium der José Carreras Leukämie Stiftung, Robert-Bosch-Stiftung.
Abstract (Originalsprache)
The family/class of the large B-cell lymphomas (LBCL) in the 5th edition of the World Health Organization (WHO) classification of haematolymphoid tumors (WHO-HAEM5) features only a few major changes as compared to the 4th edition. In most entities, there are only subtle changes, many of them only representing some minor modifications in diagnostic terms. Major changes have been made in the diffuse large B-cell lymphomas (DLBCL)/high-grade B-cell lymphomas (HGBL) associated with MYC and BCL2 and/or BCL6 rearrangements. This category now consists of MYC and BCL2 rearranged cases exclusively, while the MYC/BCL6 double hit lymphomas now constitute genetic subtypes of DLBCL, not otherwise specified (NOS) or of HGBL, NOS. Other major changes are the conceptual merger of lymphomas arising in immune-privileged sites and the description of LBCL arising in the setting of immune dysregulation/deficiency. In addition, novel findings concerning underlying biological mechanisms in the pathogenesis of the different entities are provided.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Pathology, Robert-Bosch-Krankenhaus, 70376 Stuttgart, Germany.
- Department of Pathology, Marienhospital, 70199 Stuttgart, Germany.
- Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, 70376 Stuttgart, Germany.
ORCID-Profile: Annette M Staiger
Förderung
- Robert-Bosch-Stiftung (project O3), Stuttgart, Germany. Project 3.2.4.
- Forschungsstipendium der José Carreras Leukämie Stiftung
- Robert-Bosch-Stiftung
- José Carreras Stiftung
Zitieren
APA
Kurz, K. S., Ott, M., Kalmbach, S., Steinlein, S., Kalla, C., Horn, H., Ott, G., & Staiger, A. M. (2023). Large B-Cell Lymphomas in the 5th Edition of the WHO-Classification of Haematolymphoid Neoplasms—Updated Classification and New Concepts. Cancers, 15(8), 2285. https://doi.org/10.3390/cancers15082285
Vancouver
Kurz KS, Ott M, Kalmbach S, Steinlein S, Kalla C, Horn H, et al. Large B-Cell Lymphomas in the 5th Edition of the WHO-Classification of Haematolymphoid Neoplasms—Updated Classification and New Concepts. Cancers. 2023;15(8):2285. doi:10.3390/cancers15082285
BibTeX
@article{Kurz2023,
author = {Kurz, Katrin S and Ott, Michaela and Kalmbach, Sabrina and Steinlein, Sophia and Kalla, Claudia and Horn, Heike and Ott, German and Staiger, Annette M},
title = {Large B-Cell Lymphomas in the 5th Edition of the WHO-Classification of Haematolymphoid Neoplasms—Updated Classification and New Concepts},
journal = {Cancers},
year = {2023},
volume = {15},
number = {8},
pages = {2285},
doi = {10.3390/cancers15082285}
}
EUVIMED